



**ASX RELEASE**  
**27 June 2013**

## **QRxPharma CEO discusses MOXDUO<sup>®</sup> NDA Review Update on Open Briefing**

**Sydney, Australia and Bedminster, New Jersey** – QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced yesterday the planned 17 July 2013 US Food and Drug Administration (FDA) Advisory Committee meeting to consider the MOXDUO combination opioid analgesic New Drug Application (NDA) will be delayed in order to allow the Company and the FDA time to fully consider results of recent findings for Study 022. This delay also impacts the timing of the Prescription Drug User Fee Act (PDUFA) date which was 26 August 2013.

An audio broadcast recorded today with Dr. John Holaday, Managing Director and Chief Executive Officer; Dr. Edward Rudnic, Chief Operating Officer; and Chris Campbell, Chief Financial Officer of QRxPharma discussing the MOXDUO NDA review update, is available on Open Briefing.

*To listen*, copy the following details into your web browser: **[www.openbriefing.com](http://www.openbriefing.com)** and click on the QRxPharma icon.

###

### **Media Contact information:**

Lisa Fels  
Brightline Strategies  
Tel: +1 703 739 2424 x110  
Email: [lfels@brightlinestrategies.com](mailto:lfels@brightlinestrategies.com)

Kyahn Williamson  
Buchan Consulting  
Tel: +61 401 018 828  
Email: [kwilliamson@buchanwe.com.au](mailto:kwilliamson@buchanwe.com.au)



### **About QRxPharma**

QRxPharma Limited is an Australian based, commercial-stage specialty pharmaceutical company focused on the development and commercialisation of new treatments for pain management. The Company's product portfolio includes both late and early stage clinical drug candidates with the potential for reduced risk, abbreviated development paths, and improved patient outcomes. The Company's lead product candidate, immediate release MOXDUO<sup>®</sup> for the treatment of acute pain, is presently under review at the US Food and Drug Administration. QRxPharma entered into strategic collaborations with Actavis Inc. in December 2011 and Paladin Labs Inc. in October 2012 for the commercialisation of immediate release MOXDUO<sup>®</sup> in the US and Canadian acute pain markets respectively. Additionally, the Company's clinical pipeline includes an intravenous (IV) and continuous release (CR) formulation of MOXDUO. For more information, visit [www.qrxpharma.com](http://www.qrxpharma.com).

### **Forward Looking Statements**

This release contains forward-looking statements. Forward-looking statements are statements that are not historical facts; they include statements about our beliefs and expectations. Any statement in this release that states our intentions, beliefs, expectations or predictions (and the assumptions underlying them) is a forward-looking statement. These statements are based on plans, estimates and projections as they are currently available to the management of QRxPharma. Forward-looking statements therefore speak only as of the date they are made, and we undertake no obligation to update publicly any of them in light of new information or future events. By their very nature, forward-looking statements involve risks and uncertainties. A number of important factors could therefore cause actual results to differ materially from those contained in any forward-looking statement. Such factors include risks relating to the stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialisation of the Company's proposed products.